ANDROMEDA PATIENT-LEVEL META – ANALYSIS The final word: paclitaxel DCB superior to DES at 3 years in term of MACE in the small coronary vessel disease setting.
ANDROMEDA- Skip to main content
- Skip to header right navigation
- Skip to after header navigation
- Skip to site footer
Fondazione RIC
Uniti dalla fiducia per la ricerca
